Debevoise Advises PharMEDium in $2.6 Billion Sale to AmerisourceBergen

6 October 2015

Debevoise & Plimpton LLP is advising PharMEDium, the privately held leading national provider of outsourced compounded sterile preparations (CSPs) to acute care hospitals in the United States, in its sale to AmerisourceBergen (NYSE:ABC) for $2.6 billion in cash, subject to certain adjustments and on a cash-free, debt-free basis. The transaction is subject to regulatory review and other customary closing conditions, and is expected to close in the first quarter of fiscal 2016, which ends December 31, 2015.

PharMEDium is the premier provider of customized CSPs that meet specific hospital and physician clinical needs and quality standards in formulations that are not otherwise commercially available. PharMEDium will become a part of AmerisourceBergen Drug Corporation.

The Debevoise team is led by partner Kevin A. Rinker, and includes partners Jonathan F. Lewis and Peter F.G. Schuur, counsel Stuart Hammer and associates Christopher Anthony, Uri Herzberg, Ashwin D. Phadnis and John Rothert.

In December 2013, Debevoise, again led by Mr. Rinker, advised Clayton, Dubilier & Rice (CD&R) in its acquisition of PharMEDium.

Debevoise & Plimpton LLP is a premier law firm with market-leading practices, a global perspective and strong New York roots. We deliver effective solutions to our clients’ most important legal challenges, applying clear commercial judgment and a distinctively collaborative approach.